These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12813176)

  • 21. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen for the treatment and prevention of breast cancer: an update.
    Afflitto L
    Plast Surg Nurs; 2000; 20(4):234-6. PubMed ID: 12025059
    [No Abstract]   [Full Text] [Related]  

  • 24. [Tamoxifen and breast cancer: is everything known already?].
    Marchetti P; Porzio G; Trapasso T; Baldi PL; Ficorella C
    Tumori; 1998; 84(6):A1-5. PubMed ID: 10080686
    [No Abstract]   [Full Text] [Related]  

  • 25. Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.
    Fabian C
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2210-2. PubMed ID: 18006909
    [No Abstract]   [Full Text] [Related]  

  • 26. Prevention of hormone-related cancers: breast cancer.
    Dunn BK; Wickerham DL; Ford LG
    J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen prevention claim will not be allowed in USA.
    Ault A
    Lancet; 1998 Sep; 352(9131):883. PubMed ID: 9742990
    [No Abstract]   [Full Text] [Related]  

  • 28. Tamoxifen for breast cancer in hysterectomised women.
    R Benson J
    Lancet; 2002 Nov; 360(9347):1784-5; author reply 1785. PubMed ID: 12480454
    [No Abstract]   [Full Text] [Related]  

  • 29. Tamoxifen for early breast cancer.
    Early Breast Cancer Trialists' Collaborative Group
    Cochrane Database Syst Rev; 2001; (1):CD000486. PubMed ID: 11279694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
    Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
    J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoprevention of breast cancer.
    O'Regan RM
    Cancer Treat Res; 2000; 103():183-207. PubMed ID: 10948447
    [No Abstract]   [Full Text] [Related]  

  • 32. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.
    Jordan VC
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2207-9. PubMed ID: 18006908
    [No Abstract]   [Full Text] [Related]  

  • 33. Tamoxifen for the prevention of breast cancer in high-risk women.
    Sweeney FW; Newton WP
    J Fam Pract; 1999 Feb; 48(2):90-1. PubMed ID: 10037532
    [No Abstract]   [Full Text] [Related]  

  • 34. Aromatase inhibitors and breast cancer prevention.
    Litton JK; Arun BK; Brown PH; Hortobagyi GN
    Expert Opin Pharmacother; 2012 Feb; 13(3):325-31. PubMed ID: 22242911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen dependent growth inhibitory effects of tamoxifen but not genistein in solid tumors derived from estrogen receptor positive (ER+) primary breast carcinoma MCF7: single agent and novel combined treatment approaches.
    Nobert GS; Kraak MM; Crawford S
    Bull Cancer; 2006 Jul; 93(7):E59-66. PubMed ID: 16873071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part II.
    Pritchard KI; Levine MN; Tu D
    J Clin Oncol; 2003 Feb; 21(3):399-400. PubMed ID: 12560425
    [No Abstract]   [Full Text] [Related]  

  • 37. Tamoxifen: the herald of a new era of preventive therapeutics.
    Jordan VC
    J Natl Cancer Inst; 1997 Jun; 89(11):747-9. PubMed ID: 9182965
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of tamoxifen on the endometrium.
    Barakat RR
    Oncology (Williston Park); 1995 Feb; 9(2):129-34; discussion 139-40, 142. PubMed ID: 8771096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
    Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
    Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tamoxifen for the prevention of breast cancer.
    Fisher B; Powles TJ; Pritchard KJ
    Eur J Cancer; 2000 Jan; 36(2):142-50. PubMed ID: 10741272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.